AI in GVD-to-LVD Localization: Closing Evidence Gaps Early
Discover how AI streamlines GVD-to-LVD adaptation by governing evidence, improving consistency, reducing compliance risks, and accelerating local market submissions.
.jpg)
A Global Value Dossier gets approved centrally. Three weeks later, the German affiliate is deep into adapting it for IQWiG's template when a local HEOR lead flags that a key comparative claim's RWE citation doesn't hold up under Germany's evidentiary standard. Now there's a scramble: pull new evidence, re-validate the claim, re-route it through medical, legal, and regulatory review, and hope the submission date doesn't move. This scene repeats itself across market access teams every submission cycle, and it isn't a local execution failure. It's a structural one, built into how most companies still manage the handoff from global to local dossiers.
Where Local Teams Actually Discover the Gaps in Global Evidence
Most GVD-to-LVD adaptation still runs through disconnected files, shared drives, and email threads, with no single source of truth connecting the global dossier to its local variants. Clinical, economic, and RWE evidence lives across multiple systems and formats, so there's rarely a reliable way to check whether a claim holds up in every market where it's reused until someone manually re-checks it, market by market, submission by submission.
The gap was never created during localization. It existed in the GVD from day one. It just wasn't visible until a local team tried to reuse the evidence in a new regulatory context, at which point it becomes the most expensive possible moment to discover it.
Three Structural Problems Behind the Pattern
Evidence sits in silos instead of a governed layer. Without a structured system that links every claim back to its source document, there's no systematic way to audit consistency across ten, twenty, or fifty parallel market submissions. Someone has to catch it by hand, and hand-checking doesn't scale.
Health economic models get rebuilt, not reused. Model assumptions, inputs, and narratives are typically recreated from scratch for every market adaptation. Every rebuild is a fresh opportunity to introduce an inconsistency, or to discover an assumption simply doesn't translate to a new payer environment.
Version control stops at the global document. When the GVD updates with new trial data, a revised model, or updated safety language, there's often no systematic way to see which LVDs are now out of sync with it. That's not just a productivity drag, it's a compliance and credibility risk the moment a payer or HTA reviewer spots the inconsistency.
What It Actually Takes to Catch Gaps Earlier
Moving evidence-gap discovery from the review stage back to the drafting stage comes down to two connected capabilities working together.
The first is a governed evidence layer, where evidence is structured once, tagged to its source, and linked to every claim and section where it's used. When a claim gets reused in a new market context, the system can flag whether the underlying evidence still supports it, before a local team stakes a submission timeline on it.
The second is embedded, traceable economics, where health economic model assumptions, inputs, and outputs are captured with a full audit trail, so they can be reused and adapted for a new market instead of rebuilt, with clear visibility into what changed and why.
This is the real shift AI-assisted GVD platforms are built around. It isn't about generating content faster for its own sake. It's about making evidence gaps visible at the point where they're cheapest to fix, which is drafting, not review.
Three Things That Change When the Evidence Layer Is Governed
Gaps surface during drafting and TPP alignment, not during in-market review. Instead of a local HEOR lead discovering an unsupported claim three weeks into localization, the gap gets flagged while the global team is still building the master dossier.
Model assumptions get reused instead of rebuilt. Embedded economics means the German, French, and Japanese adaptations can pull from the same governed model logic and adjust it, instead of a medical writer starting from a blank page for each one.
Markets stop working from different versions of the truth. A single, governed source of truth replaces the fragmented file-and-email handoff, so global and local teams are always adapting from the same current version of the evidence.
Bringing It All Together: Where This Fits in the GVD Lifecycle
Evidence-gap visibility isn't a standalone fix, it's one piece of a broader shift happening in how pharma companies build and maintain Global Value Dossiers. Alongside AI-driven drafting, TPP and payer alignment, modular HTA-aligned templates, and human-in-the-loop SME review, a governed evidence layer is what makes GVD-to-LVD adaptation fast without making it risky.
Agilisium's Value Dossier Agent builds this governed evidence layer directly into the authoring workflow, structuring evidence once so it can be reused, audited, and trusted across every local adaptation your team runs.
Partner with us to see how a governed evidence layer can close the gap between your global dossier and every market it needs to serve.
%20(7).avif)
%20(5).avif)
.avif)
